Cargando…

Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells

BACKGROUND: Fms-related tyrosine kinase 3 (FLT3) receptor serves as a prognostic marker and therapeutic target in acute myeloid leukemia (AML). Approximately one-third of AML patients carry mutation in FLT3, associated with unfavourable prognosis and high relapse rate. The multitargeted kinase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rörby, Emma, Adolfsson, Jörgen, Hultin, Erik, Gustafsson, Thomas, Lotfi, Kourosh, Cammenga, Jörg, Jönsson, Jan-Ingvar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852110/ https://www.ncbi.nlm.nih.gov/pubmed/33531064 http://dx.doi.org/10.1186/s40164-021-00201-w

Ejemplares similares

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Putative Role of Nuclear Factor-Kappa B But Not Hypoxia-Inducible Factor-1α in Hypoxia-Dependent Regulation of Oxidative Stress in Hematopoietic Stem and Progenitor Cells
por: Halvarsson, Camilla, et al.
Publicado: (2019)

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
por: Sierra, Jorge, et al.
Publicado: (2023)

Optimization of Inhibitory Peptides Targeting Phosphoprotein of Rabies Virus
por: Lu, Yongzhong, et al.
Publicado: (2019)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Early response evaluation in AML using mass cytometry
por: Gjertsen, Bjørn T., et al.
Publicado: (2019)

Rapid, Multiplexed Phosphoprotein Profiling Using Silicon Photonic Sensor Arrays
por: Wade, James H., et al.
Publicado: (2015)

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
por: Cattaneo, Chiara, et al.
Publicado: (2022)

Multiplex Cell Fate Tracking by Flow Cytometry
por: Rodríguez-Martínez, Marta, et al.
Publicado: (2020)

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
por: Gutierrez, Lucas, et al.
Publicado: (2018)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Early changes in gene expression profiles in AML patients during induction chemotherapy
por: Jakobsen, Ingrid, et al.
Publicado: (2022)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

A Rare Case of Midostaurin-Associated Sweet's Syndrome
por: Yasin, Hesham, et al.
Publicado: (2022)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Extended live-cell barcoding approach for multiplexed mass cytometry
por: Muftuoglu, Muharrem, et al.
Publicado: (2021)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

The stem cell regulator PEDF is dispensable for maintenance and function of hematopoietic stem cells
por: Rörby, Emma, et al.
Publicado: (2017)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
por: Pessach, Ilias, et al.
Publicado: (2022)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML
por: Cremer, Anjali, et al.
Publicado: (2023)

Mass cytometry immunostaining protocol for multiplexing clinical samples
por: Gadalla, Ramy, et al.
Publicado: (2022)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Cremer, Anjali, et al.
Publicado: (2023)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
por: Sciumè, Mariarita, et al.
Publicado: (2020)

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry
por: Ramaglia, Valeria, et al.
Publicado: (2019)

Medicago PhosphoProtein Database: a repository for Medicago truncatula phosphoprotein data
por: Rose, Christopher M., et al.
Publicado: (2012)

Multiplex analysis of antinuclear antibodies by flow cytometry using FIDIS
por: Charles, PJ
Publicado: (2004)

Rapid monoisotopic cisplatin based barcoding for multiplexed mass cytometry
por: McCarthy, Ryan L., et al.
Publicado: (2017)

Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
por: Tettero, Jesse M., et al.
Publicado: (2023)

Reduced IFN-ß inhibitory activity of Lagos bat virus phosphoproteins in human compared to Eidolon helvum bat cells
por: Papies, Jan, et al.
Publicado: (2022)

Assessment of P2Y(12) Inhibition by Clopidogrel in Feline Platelets Using Flow Cytometry Quantification of Vasodilator-Stimulated Phosphoprotein Phosphorylation
por: Li, Ronald H. L., et al.
Publicado: (2020)

Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML
por: Velasco-Hernandez, Talia, et al.
Publicado: (2018)

CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones
por: Houtsma, Roos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r1hc02uf560hjot0rhstn0p8mk